Total Utang marang Modal Estrella Bio (ESLA)

Estrella Immunopharma, Inc. - logo grafis emiten ESLA

Successes in developing T-cell leukemia treatments and FDA approvals are driving the share price growth of Estrella Immunopharma (ESLA). Intellectual capital and patents in cell therapy enable the company to monetize discoveries in partnership with pharmaceutical behemoths. The stock price history reflects the development dynamics of CAR-T R&D projects, while the total debt-to-equity ratio stands at 0.00.

estrellabio.com (ESLA): Rasio Utang marang Ekuitas saka 21.02.2024 nganti 31.10.2026

Rincian metrik lan analitis perusahaan Estrella Immunopharma Corp (ESLA)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Estrella Immunopharma, Inc.|ESLA - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar Estrella Immunopharma|ESLA - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Estrella Immunopharma|ESLA - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku estrellabio.com|ESLA - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Estrella Immunopharma|ESLA - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Estrella Immunopharma|ESLA - Kewajiban utang agregat|Utang marang nilai buku Estrella Immunopharma|ESLA - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Estrella Immunopharma|Likuiditas cepet estrellabio.com
- data bathi resik lan rasio valuasi:
ESLA - Bathi resik perusahaan
Pambiji fundamental perusahaan:Estrella Immunopharma, Inc.
Produk dadi Estrella Immunopharma

Portfolio managers are assessing the ability of Estrella Immunopharma (ESLA) to transition from the negative operating leverage of the R&D stage to the serial production of cell lines. The debt-to-equity ratio trend reflects the proportion of borrowed funds to net assets, determining the level of financial risk and the cost of servicing liabilities. Analyzing this metric provides insight into the company's margin of safety while scaling its technological platform.

Analisis pesaing Estrella Immunopharma

TGTX (TG Therapeutics) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Arcellx Inc (ACLX)|Total Utang marang Modal IRON|Total Utang marang Modal Syndax Corp (SNDX)|Utang marang Ekuitas Kura Oncology, Inc. KURA|ADCT: Rasio Utang marang Ekuitas|Foghorn - Total Utang marang Modal|Vor Biopharma, Inc. (VOR) - Rasio Total Utang marang Ekuitas|NKTX: Total Utang marang Modal|Utang marang Modal Coeptis Therapeutics, Inc. (COEP)|Utang marang Ekuitas Actinium Pharmaceuticals|CASI: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas MRKR (Marker Therapeutics)|INAB (IN8bio Inc.) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal ERNA (Eterna Therapeutics Inc.)|GT Biopharma Corporation - Utang marang Ekuitas|APTO - Utang marang Ekuitas|BPTH: Utang marang Ekuitas|MEI Pharma (MEIP) - Utang marang Ekuitas|Utang marang Modal Vincerx Pharma (VINC)